(1 - 11 von 12
)
‘Er is hoop voor kankerpatiënten' | Het Nieuwsblad
www.nieuwsblad.be
‘Moleculaire kankertherapie is de toekomst. Het zorgt voor minder bijwerkingen dan chemo, is efficiënter en bestaat intussen zo goed als voor alle kankers'...
"Met deze nieuwe therapie roeien we kanker uit" - Gazet van Antwerpen
www.gva.be
... kunnen we steeds meer patiënten helpen bij steeds meer verschillende vormen van kanker”, zegt professoroncoloog Ignace Vergote (foto).
Prima BioMed Announces Significant Updates to Its Clinical Advisory...
www.finanznachrichten.de
Prima BioMed Announces Significant Updates to Its Clinical Advisory Board: Eric Pujade-Lauraine, Christian Marth, and Ignace Vergote Join Esteemed Group of Gynecology ...
Alle artikels over "Ignace Vergote" - Data News.be
datanews.knack.be
Alle artikels over het onderwerp
Ignace Vergote, Novocure Clinical Trial Investigatorwww.novocure.com › Stories
www.novocure.com
Oct 19, · Professor Ignace Vergote conducts 20 ovarian cancer trials per year and has authored more than 800 papers in gynecologic cancers.Missing: Börm Bruckmeier" Oct 19, · Professor Ignace Vergote conducts 20 ovarian cancer trials per year and has authored more than 800 papers in gynecologic cancers. Missing: Börm Bruckmeier"
Visiting Speakers Program in Oncology | Channels
www.mcgill.ca
— Visiting Speakers Program in Oncology - Dr. Ignace Vergote "Results of the EORTC-GCG/NCIC-CTG Randomized Trial Comparing Primary Debulking vs ... › event › vis...
European Congress of Gynecological Oncology: Charité
www.charite.de
Jalid Sehouli, Germany - Congress President. Nicole Concin, Austria - ESGO President. Ignace Vergote, Belgium - Scientific Programme Committee Chair ... › service › veranstaltung › details
Turabian - AboutScience
journals.aboutscience.eu
Garbi, Annalisa, Maria Teresa Achilarre, Maria Cristina Petrella, Els Van Nieuwenhuysen, and Ignace Vergote. “Case 2 – Advanced Low-Grade Ovarian Cancer ... › get
Tumore ovarico avanzato, risultati simili con chemio ...
www.pharmastar.it
— Il lavoro, a firma di Ignace Vergote, dell'Università di Leuven, in Belgio, è stato da poco pubblicato su The Lancet Oncology. › news
Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in...
www.globenewswire.com
The study, referred to as the SIGN Study, is being led by Ignace Vergote, MD, at the University Hospitals, Leuven, Belgium. SIGN is also open at ...
Prima BioMed Announces Significant Updates to Its Clinical
www.globenewswire.com
Prima BioMed Announces Significant Updates to Its Clinical Advisory Board: Eric Pujade-Lauraine, Christian Marth, and Ignace Vergote Join ...
sortiert nach Relevanz / Datum